A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause

Trial Identifier: 2693-CL-0307
Sponsor: Astellas Pharma China, Inc.
Start Date: July 2020
Primary Completion Date: June 2022
Study Completion Date: June 2022

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
China Beijing, China
China Chengdu, China
China Guangzhou, China
China Hangzhou, China
China Hunan, China
China Jinlin, China
China Kunming, China
China Liuzhou, China
China Nanjing, China
China Nanning, China
China Ningxia Hui Nationality Autonomous Region, China
China Shanghai, China
China Shanxi, China
China Shenzhen, China
China Shijiazhuang, China
China Suzhou, China
China Taiyuan, China
China Tianjin, China
China Wuhan, China